Organogenesis

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

Retrieved on: 
Wednesday, April 3, 2024
Organogenesis, District court, Surgery, Regenerative medicine, Court, Prejudice

CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company’s motion to dismiss all claims asserted.

Key Points: 
  • CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company’s motion to dismiss all claims asserted.
  • “We are very pleased with the Court's decision,” said Lori Freedman, Chief Administrative and Legal Officer for Organogenesis.
  • “We are happy to have this behind us so we can continue to focus on our mission to substantially improve patient outcomes while lowering the overall cost of care.”

ORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Organogenesis Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, December 7, 2023
Class Action Lawsuit, Professional Services, Legal, P.C, Federation, Medicare, Jeanne Eagels, Telephone, News, Cryptocurrency, Organogenesis

Our investigation concerns whether the board of directors of Organogenesis have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Organogenesis have breached their fiduciary duties to the company.
  • On October 12, 2021, Value Investors Club issued a report alleging issues at Organogenesis Holdings, Inc., indicating that the wound care medical company has been improperly billing the federal government for $250 million annually.
  • The Company also set the price for its new wound covering, Affinity, “exorbitantly high,” which Medicare reimbursed, while making the product lucrative for doctors to use through large rebates.
  • On this news, shares of Organogenesis fell over 18% in intraday trading on October 12, 2021.

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients

Retrieved on: 
Monday, December 11, 2023
Urine, Reproduction, Skeleton, Headache, PSA, Kidney, Erythroderma, Patient, Pharmacy, Birth, Nephrotic syndrome, MBA, Cancer, Miscarriage, Safety, Incidence, VTE, Bevacizumab, Corneal opacity, Wound healing, VEGFR2, Gastrointestinal perforation, Hemoptysis, Female, Fetus, CHF, Celltrion, Pharming, Necrotizing fasciitis, Heart failure, Fistula, Risk, Tracheoesophageal fistula, Bleeding, Organogenesis, Partnership, Rhinitis, Hypertension, Primary ovarian insufficiency, Back pain, Pregnancy, Glioblastoma, PRES, Nosebleed, Skull, FDA, ATE, VEGF, MBM, Hypertensive encephalopathy, Toxicity, Nursing, Pharmaceutical industry, Birth control, Dietary supplement, Proteinuria

Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.

Key Points: 
  • Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.
  • Gastrointestinal Perforations and Fistula: Discontinue for gastrointestinal perforations, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ.
  • Surgery and Wound Healing Complications: In patients who experience wound healing complications during VEGZELMA treatment, withhold VEGZELMA until adequate wound healing.
  • Do not administer VEGZELMA for at least 28 days following a major surgery, and until adequate wound healing.

Fresenius Kabi Launches Plerixafor Injection

Retrieved on: 
Wednesday, August 9, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Hypersensitivity, NP-hardness, Fresenius (company), Diarrhea, Fetus, Multiple myeloma, Birth, Cancer, Google Store, History, Arthralgia, Anaphylaxis, Milk, Vomiting, Thrombocytopenia, B-cell lymphoma, Rupture, Animal, Organogenesis, Dizziness, Patient, Risk, Child, Nausea, Growth, G-CSF, HSC, Leukapheresis, Pregnancy, Leukemia, FDA, Headache, White, Fatigue, Pharmaceutical industry, Vaccine, Birth control, Medical imaging, Plerixafor

Fresenius Kabi announced today it has introduced Plerixafor Injection, a generic equivalent to Mozobil®, available immediately in the United States in a 24 mg per 1.2 mL single dose vial.

Key Points: 
  • Fresenius Kabi announced today it has introduced Plerixafor Injection, a generic equivalent to Mozobil®, available immediately in the United States in a 24 mg per 1.2 mL single dose vial.
  • “Fresenius Kabi is pleased to add Plerixafor Injection to our oncology portfolio, further demonstrating our commitment to expanding access to high-quality and cost-effective oncology medicines in the United States,” said John Ducker, president and CEO of Fresenius Kabi USA.
  • Plerixafor is contraindicated in patients with a history of hypersensitivity to Plerixafor.
  • This Important Safety Information does not include all the information needed to use Plerixafor Injection safely and effectively.

US Cell & Gene Therapy Market Report 2023-2028: Industry Expected to Grow at a CAGR of 41.25% - ResearchAndMarkets.com

Retrieved on: 
Friday, June 23, 2023
Health, Pharmaceutical, Spark Therapeutics, Amgen, Gilead Sciences, PTC Therapeutics, BioMarin Pharmaceutical, Cancer, Organogenesis, Telephone numbers in South Africa, Bristol Myers Squibb, AAV, Stem cell, Food and Drug Administration Safety and Innovation Act, CAR, CDMO, Novartis, Blood, Cell, Conditional sentence, Growth, Rare, FDA, Therapy, Food, Vaccine, Pharmaceutical industry, Tisagenlecleucel

This report offers market size & forecast data for the cell & gene therapy market in the US.

Key Points: 
  • This report offers market size & forecast data for the cell & gene therapy market in the US.
  • The report covers commercial cell & gene therapy products, such as conventional cell therapies, CAR-T cell therapies, gene therapies, cell-based immunotherapies, and oncolytic virus therapies.
  • This report provides a comprehensive and current market scenario of the US cell & gene therapy market, including the US cell & gene therapy market size, anticipated market forecast, relevant market segmentations, and industry trends.
  • The study considers a detailed scenario of the present cell and gene therapy market and its market dynamics for 2023-2028 in the US.

AVROBIO Announces Leadership Transition

Retrieved on: 
Monday, May 1, 2023
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, BS, Faron Pharmaceuticals, SVB Securities, University, Mackay, Business, Lead, Organogenesis, Babson College, MBA, Glycogen storage disease, David G. Booth, Economics, PwC, Science, AVRO, Patient, CFO, Growth, Therapy, DSM-IV codes, Disease, Management, Pharmaceutical industry

“On behalf of the entire board and the AVROBIO team, we thank Geoff for his eight-year commitment, building a purpose-driven company, aiming to free patients from a lifetime of genetic disease.

Key Points: 
  • “On behalf of the entire board and the AVROBIO team, we thank Geoff for his eight-year commitment, building a purpose-driven company, aiming to free patients from a lifetime of genetic disease.
  • We wish him great success in his next endeavor,” said Bruce Booth, D.Phil., chairman of the AVROBIO board of directors.
  • “As AVROBIO prepares to transition to late-stage development in two exciting programs, Erik will provide steady leadership.
  • A four-year veteran of the company, he has taken on increasing operational and leadership responsibilities over the past few years.

Organogenesis President and Chief Executive Officer Gary S. Gillheeney, Sr. Elected Chair of the Board of Directors

Retrieved on: 
Thursday, April 27, 2023
Lead, Chairperson, Surgery, Audit committee, Regenerative medicine, Art, Growth, Management, Organogenesis

Gillheeney will continue in his role as President and Chief Executive Officer, which he has held since 2014.

Key Points: 
  • Gillheeney will continue in his role as President and Chief Executive Officer, which he has held since 2014.
  • Mr. Gillheeney succeeds Alan A. Ades, who has served as a director and as Chair of the Board since 2003.
  • Mr. Ades will continue to serve as a director on the Company’s eleven-member Board of Directors.
  • It is a privilege to lead the Board, our executive team and approximately 1,000 Organogenesis employees worldwide.

Germany Cell and Gene Therapy Market Report 2023: Players Include Novartis, Gilead Sciences, Spark Therapeutics, Amgen and Orchard Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 4, 2023
Health, Pharmaceutical, European Medicines Agency, Spark Therapeutics, Tissue, Amgen, Gilead Sciences, PTC Therapeutics, Gene, BioMarin Pharmaceutical, Cancer, Organogenesis, ATMP, Bristol Myers Squibb, DSM-IV codes, Cell, Stem cell, Government, EMA, CAR, Novartis, Blood, Conditional sentence, Growth, Rare, Therapy, Fine chemical, Pharmaceutical industry, Vaccine, Tisagenlecleucel

This report offers market size & forecast data for cell & gene therapy market in Germany.

Key Points: 
  • This report offers market size & forecast data for cell & gene therapy market in Germany.
  • The report covers commercial cell & gene therapy products, such as conventional cell therapies, CAR-T cell therapies, gene therapies, cell-based immunotherapies, and oncolytic virus therapies.
  • This report provides a comprehensive and current market scenario of the Germany cell & gene therapy market, including the Germany cell & gene therapy market size, anticipated market forecast, relevant market segmentations, and industry trends.
  • Novartis, Gilead Sciences, Spark Therapeutics, Amgen, Orchard Therapeutics, Bristol-Myers Squibb, BioMarin, PTC Therapeutics, and Organogenesis are the leading players in the Europe cell and gene therapy market.

Organogenesis Applauds Findings from the Office of Inspector General

Retrieved on: 
Monday, March 27, 2023
ASP, CMS, ASPS, OIG, Office of Inspector General, U.S. Department of Health and Human Services, Surgery, HHS, Centers for Medicare & Medicaid Services, Medicare Part D, Regenerative medicine, Medicare, United States Department of Justice Office of the Inspector General, FDA, BLA, Skin, Pharmaceutical industry, Organogenesis

CANTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, applauds the findings by the Office of the Inspector General (OIG) of the U.S. Department of Health and Human Services (HHS) that transitioning all skin substitute products to average sales price (ASP) -based payments has the potential to substantially reduce Medicare Part B expenditures.

Key Points: 
  • CANTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, applauds the findings by the Office of the Inspector General (OIG) of the U.S. Department of Health and Human Services (HHS) that transitioning all skin substitute products to average sales price (ASP) -based payments has the potential to substantially reduce Medicare Part B expenditures.
  • In the report , entitled “Some Skin Substitute Manufacturers Did Not Comply with New ASP Reporting Requirements,” OIG concluded Centers for Medicare and Medicaid Services (CMS) could potentially save tens of millions of dollars per quarter if it uniformly used the ASP payment methodology for all skin substitutes.
  • “CMS has made progress in the last six months by expanding the number of skin substitutes that are being paid on the basis of ASP,” said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis.
  • “Transitioning all skin substitutes to ASP-based payments should improve access to more efficacious treatment options such as human cell and tissue-based products (HCT/Ps), and according to the report, lower the cost to the Medicare trust fund.”   Gillheeney added, “ASP-based payments are an important step in stabilizing the skin substitute market and creating a level-playing field.

Europe Cell and Gene Therapy Market Report 2023: Sector to Reach $15.15 Billion by 2028 at a 38.2% CAGR - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 28, 2023
Biotechnology, Genetics, Health, European Medicines Agency, Spark Therapeutics, Tissue, Amgen, Gilead Sciences, PTC Therapeutics, Gene, BioMarin Pharmaceutical, Cancer, Organogenesis, ATMP, Bristol Myers Squibb, DSM-IV codes, Cell, Stem cell, Government, EMA, CAR, Novartis, Blood, Conditional sentence, Growth, Rare, Therapy, Vaccine, Pharmaceutical industry, Tisagenlecleucel

This report offers market size & forecast data for cell & gene therapy market in Europe.

Key Points: 
  • This report offers market size & forecast data for cell & gene therapy market in Europe.
  • The report covers commercial cell & gene therapy products, such as conventional cell therapies, CAR-T cell therapies, gene therapies, cell-based immunotherapies, and oncolytic virus therapies.
  • This report provides a comprehensive and current market scenario of the Europe cell & gene therapy market, including the Europe cell & gene therapy market size, anticipated market forecast, relevant market segmentations, and industry trends.
  • The study considers a detailed scenario of the present cell and gene therapy market and its market dynamics for 2023-2028 in Europe.